← feed

Is NCT03060980 results overdue?

Yes — results are overdue. Primary completion was 2018-01-26; the FDAAA-801 reporting deadline (2019-01-26) passed 2703 days ago and no results are posted on ClinicalTrials.gov.

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

NCT IDNCT03060980 ↗
SponsorIntarcia Therapeutics (INDUSTRY)
PhasePHASE3
StatusTERMINATED
Primary completion2018-01-26 (ACTUAL)
Reporting deadline2019-01-26 (completion + 365d)
Days overdue2703
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 68b5a891efd4f683… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03060980. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →